Recs

5

Pharmacyclics Shares Surged: What You Need to Know

By | More Articles
February 10, 2012 | Comments (2)

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of drug developer Pharmacyclics (Nasdaq: PCYC  ) are soaring 15% after the company blew Wall Street's second-quarter estimates.

So what: In December, Pharmacyclics entered into a collaborative deal with Jaansen Pharmaceuticals, a subsidiary of Johnson & Johnson, which resulted in an upfront payment of $150 million and potential royalties of up to $1 billion. This payment resulted in Pharmacyclics recording $77.9 million in revenue and a profit of $0.82, excluding one-time items. Now compare this to Wall Street's expectations for just $2.9 million in revenue and a loss of $0.19, and you'll understand why the company is surging so much today.

Now what: Up until now, I have been brutally wrong with my underperform call on Pharmacyclics. The company has set up some very lucrative partnerships and has ample cash to conduct the 11 clinical trials currently under way. Still, with no trials past phase 2, I can't help but be skeptical of Pharmacyclics' $1.6 billion valuation. Until Pharmacyclics has an approved drug, there's simply no value left in the stock price.

Craving more input? Start by adding Pharmacyclics to your free and personalized watchlist so you can keep up on the latest news with the company.

More Expert Advice from The Motley Fool
The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock in our brand-new free report: "The Motley Fool's Top Stock for 2013." I invite you to take a copy, free for a limited time. Just click here to access the report and find out the name of this under-the-radar company.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (2) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 10, 2012, at 3:02 PM, valutrap wrote:

    "Until Pharmacyclics has an approved drug, there's simply no value left in the stock price."

    ...What about perceived value and potential revenue of the drug if it is approved. Unfortunately in risky investments like these, the lions share of the gains are made well before the drug hits the market. If PCYC's BTK inhibitor does hit the market, I wouldn't be surprised to see the valuation north of 6-8 billion the day it is approved.

  • Report this Comment On February 10, 2012, at 5:01 PM, malibusunsetter wrote:

    Watch for fast track of MCL indication. Remarkable article by someone who actually does DD.

    http://seekingalpha.com/article/314646-5-winners-of-american...

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 1778703, ~/Articles/ArticleHandler.aspx, 5/21/2013 3:27:35 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 6 hours ago Sponsored by:
DOW 15,335.28 -19.12 -0.12%
S&P 500 1,666.29 -1.18 -0.07%
NASD 3,496.43 -2.54 -0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/20/2013 4:00 PM
PCYC $81.86 Down -3.03 -3.57%
PHARMACYCLICS, INC… CAPS Rating: *

Advertisement